Cardiff Oncology, Inc. (CRDF) — 10-Q Filings
All 10-Q filings from Cardiff Oncology, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Cardiff Oncology's Q3 Net Loss Narrows, Cash Reserves Dwindle
— Nov 6, 2025 Risk: high
Cardiff Oncology, Inc. (CRDF) reported a net loss of $11.258 million for the three months ended September 30, 2025, a slight improvement from the $11.855 millio -
Cardiff Oncology's Q2 Net Loss Widens to $14.1M Amid R&D Spend
— Jul 29, 2025 Risk: high
Cardiff Oncology, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss fo -
Cardiff Oncology Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Cardiff Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial item -
Cardiff Oncology Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
Cardiff Oncology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and operational updates. Key financial fi -
Cardiff Oncology Q2 2024: Net Loss of $16.9M
— Aug 8, 2024 Risk: medium
Cardiff Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $101.8 million and total liabilities of $13.1 mi -
Cardiff Oncology, Inc. Files 10-Q for Period Ending March 31, 2024
— May 2, 2024 Risk: low
Cardiff Oncology, Inc. (CRDF) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Cardiff Oncology, Inc. filed a 10-Q report for the period ending Marc
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX